Standout Papers
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (2011)
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis (2006)
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis (2012)
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012)
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (2012)
- Multiple sclerosis: emerging epidemiological trends and redefining the clinical course (2024)
Immediate Impact
2 by Nobel laureates 9 from Science/Nature 98 standout
Citing Papers
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
2025 Standout
Multiple sclerosis
2023 Standout
Works of Eva Havrdová being referenced
Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review
2017
Survey of diagnostic and treatment practices for multiple sclerosis in Europe
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Eva Havrdová | 18266 | 5102 | 4692 | 6056 | 376 | 22.9k | |
| Michael Hutchinson | 13557 | 3536 | 3546 | 6440 | 293 | 21.3k | |
| Paul O’Connor | 18965 | 4762 | 4684 | 6632 | 148 | 24.1k | |
| Emmanuelle Waubant | 14895 | 2839 | 3558 | 5953 | 221 | 20.4k | |
| Jerry S. Wolinsky | 22921 | 3949 | 6349 | 8479 | 241 | 27.9k | |
| George C. Ebers | 22503 | 4067 | 6737 | 7369 | 351 | 31.2k | |
| Per Soelberg Sørensen | 12765 | 3734 | 3314 | 5590 | 432 | 21.1k | |
| Richard A. Rudick | 15635 | 3332 | 4048 | 5405 | 210 | 21.2k | |
| Jeffrey A. Cohen | 12816 | 3067 | 3095 | 5496 | 305 | 22.0k | |
| Gavin Giovannoni | 13537 | 4274 | 3127 | 6959 | 667 | 25.2k | |
| Amit Bar‐Or | 14073 | 3869 | 3229 | 5667 | 447 | 25.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...